NASDAQ:NTRP - Neurotrope Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.94
+0.30 (1.20%)
Get New Neurotrope Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NTRP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NTRP

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Neurotrope in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.94.

This chart shows the closing price for NTRP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Neurotrope. This rating has held steady since September 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/12/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/10/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/9/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/7/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/5/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/4/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/11/2019Janney Montgomery ScottDowngradeBuy ➝ Neutral$13.00 ➝ $1.00Medium
9/9/2019Maxim GroupDowngradeBuy ➝ HoldN/A
6/18/2019Janney Montgomery ScottInitiated CoverageBuy ➝ Buy$14.00High
2/5/2019Maxim GroupReiterated RatingBuy$16.00Medium
10/22/2018Maxim GroupSet Price TargetBuy$16.00Medium
9/6/2018Maxim GroupSet Price TargetBuy$16.00Low
8/13/2018Maxim GroupReiterated RatingBuy$16.00Low
7/12/2018Maxim GroupSet Price TargetBuy$16.00High
7/2/2018Maxim GroupSet Price TargetBuy$16.00Low
5/16/2018Maxim GroupInitiated CoverageBuy$16.00High
3/8/2018Roth CapitalInitiated CoverageBuy ➝ Buy$15.00Medium
5/2/2017AegisReiterated RatingBuy$31.00N/A
4/19/2017AegisReiterated RatingBuy$31.00N/A
4/12/2017AegisInitiated CoverageBuy$31.00N/A
(Data available from 12/4/2016 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/8/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/7/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/7/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/6/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/5/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/5/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/4/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/4/2021

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Neurotrope logo
Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. The company's lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.
Read More

Today's Range

Now: $0.94
Low: $0.94
High: $0.94

50 Day Range

MA: $0.96
Low: $0.92
High: $1.05

52 Week Range

Now: $0.94
Low: $0.68
High: $3.85

Volume

N/A

Average Volume

597,206 shs

Market Capitalization

$22.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.27

Frequently Asked Questions

What sell-side analysts currently cover shares of Neurotrope?

The following Wall Street analysts have issued research reports on Neurotrope in the last year:
View the latest analyst ratings for NTRP.

What is the current price target for Neurotrope?

0 Wall Street analysts have set twelve-month price targets for Neurotrope in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Neurotrope in the next year.
View the latest price targets for NTRP.

What is the current consensus analyst rating for Neurotrope?

Neurotrope currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for NTRP.

How do I contact Neurotrope's investor relations team?

Neurotrope's physical mailing address is 1185 AVENUE OF THE AMERICAS 3RD FLOOR, NEW YORK NY, 10036. The company's listed phone number is 973-242-0005 and its investor relations email address is [email protected] The official website for Neurotrope is www.neurotropebioscience.com.